Study of Olverembatinib (HQP1351) in Patients With CML-CP
This research study is investigating a new medication called olverembatinib for patients with Chronic Myeloid Leukemia (CML) in its chronic phase (CML-CP). The study has two main parts. One part compares how well olverembatinib works and its safety against an approved medicine called bosutinib. The other part specifically looks at olverembatinib in patients who have a particular genetic change in their CML, known as the T315I mutation. The aim is to see if olverembatinib is a safe and effective new treatment option for people living with CML-CP, especially for those who might not have other good treatment choices.
במבט חטוף
על מה המחקר הזה?
This research study is about finding new and better ways to treat a type of blood cancer called Chronic Myeloid Leukemia (CML). Specifically, it focuses on CML in its early, chronic phase (CML-CP). For people with CML-CP, treatments often involve medicines that target the cancer cells. However, sometimes these treatments stop working, or patients develop specific changes in their cancer cells that make current medicines less effective.
The study has two main goals. The first part compares a new, experimental medicine called olverembatinib with a medicine that's already approved and used, called bosutinib. This is to see which medicine works better and is safer for people with CML-CP who have already tried at least two other similar treatments. The second part of the study looks at olverembatinib on its own, for people with CML-CP who have a specific genetic change (called a T315I mutation) in their cancer cells. This mutation can make some CML medicines less effective, so finding new options is very important.
The overall aim of this study is to gather information that will help doctors understand if olverembatinib could be a useful new treatment option for people with CML-CP, especially for those who need more choices. If the study shows that olverembatinib is safe and effective, it could become available to more patients in the future.
נקודות עיקריות
- The study explores a new CML medicine called olverembatinib.
- It aims to find better treatments for CML, especially when other medicines haven't worked or for specific genetic changes.
- Participation involves taking medication and attending regular check-ups.
- There are potential benefits and risks, which your doctor will explain fully.
- You can stop participating in the study at any time without affecting your normal care.
מי עשוי להיות זכאי?
To join this study, you need to be at least 18 years old and have a diagnosis of Chronic Myeloid Leukemia in its chronic phase (CML-CP). For the first part of the study (comparing olverembatinib with bosutinib), you must have already tried at least two other similar CML medicines. For the second part (for people with a specific genetic change), you need to have the T315I mutation and have tried at least one other CML medicine, without other good treatment options available.
Your general health also needs to be good enough to take part. This means your body's organs should be working properly, and you should be able to carry out most of your usual daily activities without too much difficulty. A doctor will check these things to make sure the study is safe for you.
However, there are some reasons why you might not be able to join. For example, if you have a certain genetic change (T315I or V299L) *before* starting treatment in the comparison part of the study. You also can't join if you have an active infection, problems with your gut that might affect how the medicine works, or if you've had a bad reaction to the study drugs before. Pregnant or breastfeeding women cannot participate.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- האם אתה בן 18 או יותר?
- Have you been diagnosed with CML-CP (Chronic Myeloid Leukemia - Chronic Phase)?
- Have you already tried at least two other CML medicines (or one if you have the T315I gene change)?
- Are you generally well enough to do most daily activities?
- האם את לא בהריון או מניקה?
מה כרוך בהשתתפות?
If you decide to take part in this study, you will be given either the new medicine (olverembatinib) or an existing one (bosutinib) as tablets. The study will involve regular visits to the hospital or clinic where doctors and nurses will monitor your health, check how you are responding to the treatment, and look for any side effects. These checks will include blood tests, physical examinations, and possibly other tests.
For the first part of the study, you won't know whether you're getting olverembatinib or bosutinib, but both are active treatments. For the second part, everyone receives olverembatinib. If you are in the comparison part and your current treatment stops working, you might have the option to switch to olverembatinib later on. The total duration of your participation, including treatment and follow-up, will be explained in detail by the study team, as it can vary.
סיכונים ותועלות פוטנציאליים
Locations (163)
- Ascentage Investigative Site #1044מיקוד מאומתבירמינגהם, ארצות הברית· גיוס
- Ascentage Investigative Site #1112מיקוד מאומתאנקורג', ארצות הברית· גיוס
- Ascentage Investigative Site #1111מיקוד מאומתGoodyear, United States· גיוס
- Ascentage Investigative Site #1062מיקוד מאומתדוארטה, ארצות הברית· גיוס
- Ascentage Investigative Site #1099מיקוד מאומתאירוויין, ארצות הברית· גיוס
- Ascentage Investigative Site #1075מיקוד מאומתלה הויה, ארצות הברית· גיוס
- Ascentage Investigative Site #1100מיקוד מאומתלונג ביץ', ארצות הברית· גיוס
- Ascentage Investigative Site #1059מיקוד מאומתלוס אנג'לס, ארצות הברית· גיוס
- Ascentage Investigative Site #1121מיקוד מאומתסקרמנטו, ארצות הברית· גיוס
- Ascentage Investigative Site #1109מיקוד מאומתUpland, United States· גיוס
- Ascentage Investigative Site #1045מיקוד מאומתאוגוסטה, ארצות הברית· גיוס
- Ascentage Investigative Site #1110מיקוד מאומתNewnan, United States· גיוס
שאלות נפוצות
What is CML-CP?
CML-CP stands for Chronic Myeloid Leukemia - Chronic Phase. It's a type of blood cancer that starts in the bone marrow, and the chronic phase is usually the earlier, slower-progressing stage of the disease.
What is olverembatinib?
Olverembatinib is a new medicine being tested in this study. It's designed to treat CML by targeting specific pathways that help cancer cells grow. It's not yet approved for general use.
What is the T315I mutation?
The T315I mutation is a specific change in the genetic make-up of CML cancer cells. This change can sometimes make certain CML medicines less effective, so new treatments are needed for people with this mutation.
האם אדע איזו תרופה אני מקבל?
If you are in the part of the study comparing olverembatinib and bosutinib, you will not know which medicine you are receiving. If you are in the part looking at the T315I mutation, you will receive olverembatinib.
האם אני יכול לעזוב את המחקר בכל עת?
Yes, you have the right to withdraw from the study at any point, for any reason, without it affecting your medical care.
כיצד לגלות עוד
Ascentage Clinical Operations
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
מעוניינים להשתתף?
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.